Bio-Rad Laboratories, Inc.
BIO
$279.03
-$5.65-1.99%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.58B | 2.56B | 2.55B | 2.54B | 2.57B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.58B | 2.56B | 2.55B | 2.54B | 2.57B |
| Cost of Revenue | 1.24B | 1.20B | 1.19B | 1.16B | 1.17B |
| Gross Profit | 1.34B | 1.35B | 1.37B | 1.38B | 1.39B |
| SG&A Expenses | 820.10M | 805.60M | 800.90M | 791.60M | 808.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.32B | 2.28B | 2.28B | 2.25B | 2.28B |
| Operating Income | 265.90M | 277.10M | 275.10M | 296.00M | 290.80M |
| Income Before Tax | 995.50M | -842.60M | 450.10M | -2.75B | -2.34B |
| Income Tax Expenses | 235.60M | -166.70M | 130.90M | -586.10M | -498.30M |
| Earnings from Continuing Operations | 759.90 | -675.90 | 319.20 | -2.16K | -1.84K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 759.90M | -675.90M | 319.20M | -2.16B | -1.84B |
| EBIT | 265.90M | 277.10M | 275.10M | 296.00M | 290.80M |
| EBITDA | 431.30M | 439.20M | 431.90M | 448.60M | 442.40M |
| EPS Basic | 27.95 | -24.30 | 11.77 | -76.17 | -65.00 |
| Normalized Basic EPS | 7.31 | 7.14 | 7.00 | 7.51 | 7.29 |
| EPS Diluted | 27.91 | -24.31 | 11.73 | -76.20 | -65.04 |
| Normalized Diluted EPS | 7.31 | 7.14 | 6.99 | 7.50 | 7.29 |
| Average Basic Shares Outstanding | 109.07M | 110.09M | 111.11M | 112.28M | 112.86M |
| Average Diluted Shares Outstanding | 109.12M | 110.10M | 111.17M | 112.33M | 112.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |